Beiersdorf
Beiersdorf is a seed to Series C stage investment firm. It has made 9 investments. 40% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 3 prior). Their most common stage is series-a (40% of deals). Average disclosed round size is $46.8M (across 3 rounds with reported amounts).
Portfolio
9
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Melt&Marble | Series A | — | Dec 2025 |
 Dermanostic | Series A | — | Jun 2025 |
 DePoly | Seed | $23M | Jan 2025 |
 DeepLife | Series A | — | Dec 2024 |
 Evommune | Series C | $115M | Oct 2024 |
| Melt&Marble | Unknown | — | Jan 2024 |
| SSalvalco | Unknown | — | May 2022 |
| MMacro Biologics | Unknown | $2.5M | Jan 2020 |
 S-Biomedic | Series A | — | Jan 2019 |
 Cellvie | Seed | — | — |
Top Co-Investors
Beiersdorf Venture Capital6 shared
dsm-firmenich Ventures1 shared
Johnson & Johnson Innovation1 shared
Life Extension Ventures1 shared
Foresight Williams Technology1 shared
DvH Ventures1 shared
private angel investors1 shared
Industrifonden1 shared
Calm Ventures1 shared
Andera Partners1 shared
Next Capital1 shared
Amplitude Ventures1 shared
EQT Life Sciences1 shared
RTW Investments, LP1 shared
Adage Capital Management1 shared
Longwood Fund1 shared
W Health Ventures1 shared
B Capital1 shared
SymBiosis1 shared
Last updated: 7 October 2026